Vaccines and Public Health
Adult immunization rates are falling short of national targets. Learn how global, federal, and state policies affect vaccination uptake. Leverage our findings to guide your strategies. Rely on our expertise commercializing novel and therapeutic vaccines.
Using Diagnostics to Mitigate the COVID-19 Public Health Emergency
Mitigating the public health emergency (PHE) caused by SARS-CoV-2 requires a multifaceted approach.
Interview: Community Use of Face Masks and COVID-19: Evidence from a Natural Experiment of State Mandates in the US
Tune into another episode of Avalere’s Journal Club Review podcast series on Avalere Health Essential Voice. In this segment, our health policy experts discuss a recent study on the effectiveness of statewide mask mandates in reducing the spread of COVID-19, and the implications of its findings on future policy interventions.
Who Will Approve a COVID Vaccine in the US?
As life sciences companies sprint toward COVID-19 vaccines and therapies, the discussion below considers who has the authority to make the call on their availability at the Food and Drug Administration (FDA) and the US Department of Health and Human Services (HHS).
Interview: Vaccines Outlook: Hesitancy, Uptake, and Infrastructure with Dr. Angela Shen
Tune into another episode of Start Your Day with Avalere. In this segment, vaccines experts Richard Hughes IV and Dr. Angela Shen discuss the issue of vaccine hesitancy and the gaps in infrastructure and policy that affect adult vaccine uptake.
CMS Proposal Would Increase Provider Payment for Vaccine Administration
The proposed CY 2020 MPFS rule includes provisions that, if finalized, would increase provider reimbursement for vaccine administration. However, the proposed crosswalk of the codes to a separate, nonvaccine related code could subject the code to future unrelated payment fluctuations.
Interview: Vaccines Outlook: Adult Vaccine Access with Abby Bownas
Tune into another episode of Start Your Day with Avalere. In this segment, experts from our vaccines team discuss challenges within the vaccines marketplace and highlight the efforts currently underway to improve access and uptake among adults.
Bringing COVID-19 Vaccines and Therapeutics to Market
On July 22, Avalere experts discussed the marketplace for COVID-19 vaccines and therapeutics in the “Cutting Through the Noise: Market Evolution and Pathways to Access for COVID-19 Vaccines and Therapeutics” webinar. They examined FDA regulatory considerations, coverage and access challenges, and key pricing and distribution scenarios for optimal US market access.
Interview: 2020 Mid-Year Vaccines Outlook
Tune into another episode of Start Your Day with Avalere. In this segment, experts from our vaccines team discuss the general outlook for the vaccines marketplace and pipeline.
Avalere Vaccines: 2020 Mid-Year Outlook
Vaccine development is at the forefront of global efforts to address the COVID-19 pandemic, with a rapidly growing pipeline of candidates that will expand the existing vaccine landscape.
Webinar: Cutting Through the Noise: Market Evolution and Pathways to Access for COVID-19 Vaccines and Therapeutics
Avalere experts discussed the marketplace for COVID-19 vaccines and therapeutics, including key decision points for regulatory pathways, pricing, and distribution scenarios for optimal US and EX-US market access.
The State of COVID-19 Vaccine Candidate Development
The novel coronavirus (COVID-19) was first reported in Wuhan, China, on December 31, 2019, and within a month was declared a public health emergency of international concern (PHEIC) by the World Health Organization (WHO).
Medicare Spent $106B on Vaccine-Preventable Diseases Over 3 Years
Avalere analysis finds Medicare incurred $106.4 billion in 2016–2018 treating diseases potentially preventable with inline vaccines and select pipeline vaccine candidates. Those diseases also resulted in beneficiary costs of approximately $9.6 billion during the same time period.
Post-COVID-19 Considerations for the Commercial Health Coverage Market
Faced with a rapidly evolving healthcare environment, there are a number of important uncertainties that commercial insurers will need to consider when planning for the future
Opportunities to Modernize the Vaccine Injury Compensation Program
A proposal to eliminate shoulder injuries from the list of vaccine-related conditions that warrant federal compensation through the National Vaccine Injury Compensation Program (VICP) highlights the administrative challenges posed by these claims and provides an opportunity to consider reforms to modernize the program.
COVID-19 is Stressing a Fractured Mental Healthcare System in the US
Mental Health Awareness Month and the COVID-19 crisis intersect—and highlight challenges in the US mental health care system
Insights from the Influenza Vaccine Market for COVID-19 Vaccines
The evolution of the US influenza vaccine market offers insights into the potential barriers and opportunities for successful rollouts of novel COVID-19 vaccines.
COVID-19 and Its Impact on the Global Drug Supply Chain
Although COVID-19 is introducing new challenges within the global pharmaceutical supply chain, the current situation also creates opportunities for stakeholders to evaluate drug security and implement risk-mitigation strategies around shortages and required stockpiles.
The Impact of COVID-19 on the Health Insurance Industry
On April 9, Avalere experts came together to discuss the impact of COVID-19 on the health insurance industry.
Reducing Funding to WHO May Impact Existing Vaccines Programs
On April 15, President Trump announced his intention to halt funding to the World Health Organization (WHO), pending an investigation into WHO’s response to the COVID-19 pandemic. WHO first declared the outbreak a Public Health Emergency of International Concern on January 30 and a global pandemic on March 11. A reduction in funding from the US could limit WHO’s COVID-19 response activities as well as its regular vaccine programming, including product prequalification, global surveillance, and ongoing efforts to strengthen health systems.
Impact of the COVID-19 Pandemic on Sickle Cell Disease Management
Sickle cell disease (SCD) is a severe red blood cell disorder that disproportionately affects African-American and Hispanic populations. In the United States, there are approximately 100,000 individuals living with SCD (although there is a lack of accurate reporting and the exact number is unknown).